Patents Represented by Attorney Dechert LLP
  • Patent number: 7842293
    Abstract: The present disclosure provides methods for treating multiple myeloma comprising administering to a subject with multiple myeloma the anti-CS1 antibody HuLuc63 in combination with dexamethasone and, optionally, thalidomide.
    Type: Grant
    Filed: August 7, 2007
    Date of Patent: November 30, 2010
    Assignee: Facet Biotech Corporation
    Inventor: Daniel Afar
  • Patent number: 7833767
    Abstract: The present invention is directed to variant polypeptides having enhanced ketoreductase activity and/or thermostability for use in the stereospecific reduction of ketones. In addition, the present invention is directed to polynucleotides that encode the ketoreductase polypeptides, including codon optimized versions of the polynucleotides which provide for enhanced expression in host cells. In another aspect, the present invention is directed to nucleotide constructs, vectors and host cells that are transformed with polynucleotides of the present invention.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: November 16, 2010
    Assignee: Codexis, Inc.
    Inventors: S. Christopher Davis, Gjalt W. Huisman, Stephane J. Jenne, Anke Krebber, Lisa Marie Newman
  • Patent number: 7829576
    Abstract: This present disclosure provides methods of treating pain with beloxepin and/or beloxepin analogs.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: November 9, 2010
    Assignee: Adolor Corporation
    Inventors: Bertrand Le Bourdonnec, Roland E. Dolle
  • Patent number: 7824898
    Abstract: The present invention relates to novel halohydrin dehalogenase polypeptides and the polynucleotides that encode them. These polypeptides are useful in the production of 4-substituted-3-butyric acid derivatives and vicinal cyano, hydroxyl substituted carboxylic acid esters. The invention also provides related vectors, host cells and methods.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: November 2, 2010
    Assignee: Codexis, Inc.
    Inventors: S. Christopher Davis, Richard John Fox, Gjalt W. Huisman, Vesna Gavrilovic, Lisa Marie Newman
  • Patent number: 7816111
    Abstract: The present invention is directed to glucose dehydrogenase (GDH) polypeptides that have enhanced GDH activity and/or thermostability relative to the backbone wild-type glucose dehydrogenase polypeptide. In addition, the present invention is directed to a polynucleotide that encodes for the GDH polypeptides of the present invention, to nucleic acid sequences comprising the polynucleotides, to expression vectors comprising the polynucleotides operatively linked to a promoter, to host cells transformed to express the GDH polypeptides, and to a method for producing the GDH polypeptides of the present invention.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: October 19, 2010
    Assignee: Codexis, Inc.
    Inventors: S. Christopher Davis, Stephane J. Jenne, Anke Kebber, Lisa Marie Newman
  • Patent number: 7811549
    Abstract: Methods are presented that comprise the administration of a pharmaceutical composition comprising adenosine and dipyridamole, as well methods comprising the combined administration of dipyridamole administered as a bolus with adenosine given as an infusion, both at dosages below their respective single agent dosages, for detecting the presence and/or assessing the severity of myocardial ischemia during pharmacologic stress tests. The methods are useful for exploiting the vasodilating abilities of adenosine at doses at which side effects related to adenosine are substantially reduced while optimal coronary artery perfusion is achieved. Also presented are compositions, unit dosage forms, and kits that are useful in performing the methods.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: October 12, 2010
    Assignee: Adenobio N.V.
    Inventor: Philippe Gorny
  • Patent number: 7807423
    Abstract: The present invention provides methods and compositions for preparing 4-substituted 3-hydroxybutyric acid derivatives by halohydrin dehalogenase-catalyzed conversion of 4-halo-3-hydroxybutyric acid derivatives. The present invention further provides methods and compositions for preparing 4-halo-3-hydroxybutyric acid derivatives by ketoreductase-catalyzed conversion of 4-halo-3-ketobutyric acid derivatives The present invention also provides methods and compositions for preparing vicinal cyano, hydroxyl substituted carboxylic acid esters.
    Type: Grant
    Filed: August 10, 2006
    Date of Patent: October 5, 2010
    Assignee: Codexis, Inc.
    Inventors: S. Christopher Davis, John H. Grate, David R. Gray, John M. Gruber, Gjalt W. Huisman, Steven K. Ma, Lisa M. Newman, Roger Sheldon, Li A Wang
  • Patent number: 7799786
    Abstract: A compound of formula: wherein A, Ar, R3, R6, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a “Cyanoiminopiperazine Compound”), compositions comprising an effective amount of a Cyanoiminopiperazine Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cyanoiminopiperazine Compound are disclosed.
    Type: Grant
    Filed: September 4, 2007
    Date of Patent: September 21, 2010
    Assignee: Purdue Pharma L.P.
    Inventors: Donald J. Kyle, Qun Sun, Laykea Tafesse, Chongwu Zhang, Xiaoming Zhou
  • Patent number: 7799807
    Abstract: The present invention discloses compounds of formula: where Ar1, Ar2, X, R1, R2, R3, m, and n are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Phenylene Compound”); compositions comprising an effective amount of a Phenylene Compound; and methods for treating or preventing pain and other conditions in an animal comprising administering to an animal in need thereof an effective amount of a Phenylene Compound.
    Type: Grant
    Filed: March 20, 2006
    Date of Patent: September 21, 2010
    Assignee: Purdue Pharma L.P.
    Inventor: Qun Sun
  • Patent number: 7775168
    Abstract: The invention pertains to apparatus and methods for injecting viscous fertilizer, such as dewatered biosolids, below the surface of the soil. The invention also pertains to apparatus and methods for creating a continuous flow of viscous material and for dividing a flow of viscous material.
    Type: Grant
    Filed: April 24, 2006
    Date of Patent: August 17, 2010
    Assignee: American Water Works Company, Inc.
    Inventors: Phil Sidhwa, Dan Goldhawk, Walter Stewart Grose, Gordon Raymond Grose
  • Patent number: 7772254
    Abstract: The present invention discloses a compound of formula: where Ar1, Ar2, X, Z1, Z2, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Pyridylene Compound”); compositions comprising an effective amount of a Pyridylene Compound; and methods for treating or preventing pain or other conditions in an animal comprising administering to an animal in need thereof an effective amount of a Pyridylene Compound.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: August 10, 2010
    Assignee: Purdue Pharma L.P.
    Inventor: Qun Sun
  • Patent number: 7767699
    Abstract: The invention provides a compound of formula (I): (where R1, Q, A and R2 are disclosed herein) or a pharmaceutically acceptable salt thereof (a “Pyridine-alkynyl Compound”); pharmaceutical compositions comprising an effective amount of a Pyridine-alkynyl Compound; and methods for treating or preventing a condition such as pain, urinary incontinence, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, a seizure, stroke, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a Pyridine-alkynyl Compound.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: August 3, 2010
    Assignee: Purdue Pharma, L.P.
    Inventors: Donald J. Kyle, Qun Sun, Xiaoming Zhou
  • Patent number: 7754723
    Abstract: Compounds of formulae: where Ar1, Ar2, R3, R4, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a “Nitro(cyano)vinylpiperazine Compound”); compositions comprising an effective amount of a Nitro(cyano)vinylpiperazine Compound; and methods for treating or preventing pain and other conditions in an animal comprising administering to an animal in need thereof an effective amount of a Nitro(cyano)vinylpiperazine Compound are disclosed.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: July 13, 2010
    Inventors: Qun Sun, Laykea Tafesse
  • Patent number: 7741309
    Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: June 22, 2010
    Assignees: Santaris Pharma A/S
    Inventors: Jens Bo Rode Hansen, Charlotte Albaek Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
  • Patent number: 7737264
    Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: June 15, 2010
    Assignees: Santaris Pharma A/S
    Inventors: Charlotte Albæk Thrue, Anja Mølhart Høg, Paul E. G. Kristjansen
  • Patent number: 7737148
    Abstract: A compound of formula: wherein Ar, Ar1, Ar2, R3-R6, R13, m, and t are disclosed herein, or a pharmaceutically acceptable salt thereof (a “Hydroxyiminopiperazine Compound”); compositions comprising an effective amount of a Hydroxyiminopiperazine Compound; and methods for treating or preventing pain and other conditions in an animal comprising administering to an animal in need thereof an effective amount of a Hydroxyiminopiperazine Compound are disclosed.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: June 15, 2010
    Assignee: Purdue Pharma, L.P.
    Inventors: Qun Sun, Xiaoming Zhou
  • Patent number: 7718639
    Abstract: 7-Hydroxyepiandrosterone may be used for protection against acute or chronic neuronal damage.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: May 18, 2010
    Assignee: Hunter-Fleming Limited
    Inventors: Ernst Wulfert, Ashley Ker Pringle, Lars Eric Sundstrom
  • Patent number: 7713738
    Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: May 11, 2010
    Assignees: Santaris Pharma A/S
    Inventors: Bo Hansen, Charlotte Albæk Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
  • Patent number: 7709610
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: May 4, 2010
    Assignee: Facet Biotech Corporation
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • Patent number: 7709523
    Abstract: ?-Aminoamide derivatives useful as antimigraine agents, particularly for the treatment of head pain conditions such as migraine, cluster headache or other severe headache, are disclosed. The antimigraine agents of the invention are able to reduce or even stop the pain deriving from such conditions without, virtually, any side effects.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: May 4, 2010
    Assignee: Newron Pharmaceuticals SpA
    Inventors: Patricia Salvati, Marcello Calabresi, Luciano Dho, Orietta Veneroni, Piero Melloni